Tag Archive for: data

Destiny Pharma plc – Landmark data published on successful NTCD-M3 gut colonisation after fidaxomicin administration

/in

Brighton, United Kingdom – 4 April 2023 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces that data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, to successfully colonise the gut following administration […]

Read more

Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure

/in

Data from GLP[i] animal studies demonstrate safety of second-generation DSR[ii] product (DSR 2.0) Data from Phase 1 study of DSR 2.0 in Mexico (CHIHUAHUA) and IND[iii] filing to US FDA expected in Q1 2023 Planning to start MOJAVE, a US Phase 1/2a randomized controlled multi-center study of DSR 2.0, in Q2 2023 Ghent, Belgium – 08 February 2023 – Sequana […]

Read more

CellCentric presents early clinical data at ASH

/in

Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma Inobrodib is an oral drug showing good long-term tolerability at the recommended phase 2 dose as monotherapy Objective responses have been observed in heavily pre-treated relapsed/ refractory multiple myeloma patients Inobrodib is also being evaluated in combination with pomalidomide/ dexamethasone, with clear […]

Read more

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

/in

 STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3  STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022  20 October 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is […]

Read more

vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

/in

Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, an important and long sought indicator of biochemical neuroprotection Combined inhibition of nitric oxide synthesis and glutamate increase expands our understanding of Ronopterin’s mode of action and its association with improved outcome in TBI Decreasing glutamate adds to the previously reported reduction in […]

Read more